Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research

Current Pharmaceutical Design

Volumn 19, Issue 37, 2013, Pages 6575-6593

  Wang, Yi Xiang J ^a,b   Xuan, Shouhu ^c   Port, Marc ^d   Idee, Jean Marc ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d Research Division   (France)

Author keywords

Cell labeling; Hyperthermia; Iron oxide nanoparticles; Magnetic targeting; MRI; SPIO; Superparamagnetic; Surface coatings; Targeted drug delivery

Indexed keywords

ATORVASTATIN; CITRIC ACID; CURCUMIN; DEXTRAN; DOXORUBICIN; DRUG CARRIER; FERRIC OXIDE; FERROCENE; FERUCARBOTRAN; FERUMOXYTOL; GADOLINIUM PENTETATE MEGLUMINE; HEPARIN; MACROGOL; MAGNETITE NANOPARTICLE; MITOXANTRONE; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOMATERIAL; NANOSHELL; PACLITAXEL; PHOSPHONIC ACID DERIVATIVE; POLYLACTIC ACID; POLYVINYL ALCOHOL; POVIDONE; SILICON DIOXIDE; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAMETHYLAMMONIUM HYDROXIDE; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG;

CANCER CELL; CAROTID ATHEROSCLEROSIS; CELL INTERACTION; CELL LABELING; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; ENCAPSULATION; GENE DELIVERY SYSTEM; HUMAN; HYPERTHERMIA; INFLAMMATORY CELL; LOW DRUG DOSE; MAGNETIC FIELD; MATERIAL COATING; MEDICAL RESEARCH; MONITORING; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SQUAMOUS CELL CARCINOMA; STEM CELL; SURFACE PROPERTY; TISSUE ENGINEERING;

ANIMALS; ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; FERRIC COMPOUNDS; HUMANS; MAGNETITE NANOPARTICLES; NEOPLASMS;

EID: 84887887561     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319370003     Document Type: Review

References (195)

1. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021.
2. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11: 2319-31.
3. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58: 1471-1504.
4. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011; 1: 35-40.
5. Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol 2004; 5: 567-84.
6. Daldrup-Link HE, Rudelius M, Piontek G, et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1. 5-T MR imaging equipment. Radiology 2005; 234: 197-205.
7. Xu H, Aguilar ZP, Yang L, Kuang M, Duan H, Xiong Y, Wei H, Wang A. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials 2011; 32: 9758-65.
8. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol. J 2011; 6: 1342-7.
9. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011; 63: 24-46.
10. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008; 3: 169-80.
11. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2005; 2: 194-205.
12. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006; 34: 23-38.
13. Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synethesis, protection, functionalization, and application. Angew. Chem. Int. Ed 2007; 46: 1222-4.
14. Welo LA, Baudisch B. The two-staye tranformation of magnetic into hematite. Philos. Mag 1925; 50: 399-408.
15. Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J. Mater. Chem 2009; 19: 6274-93.
16. Wang Z, Guo H, Yu Y, He N. Carbon-coated iron oxide nanoparticles as contrast agents in magnetic resonance imaging. Magn. Magn. Mater 2006; 302: 397-404.
17. Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008; 108: 2064-110.
18. Wang J, Sun J, Sun Q, Chen Q. One-step hydrothermal process to prepare highly crystalline Fe3O4 nanoparticles with improved magnetic properties. Mater. Res. Bul 2003; 38: 1113-8.
19. Xuan S, Hao L, Jiang W, Gong X, Hu Y, Chen Z. Preparation of water-soluble magnetic nanocrystals through hydrothermal approach. J. Magn. Magn. Mater 2007; 308: 210-3.
20. Si S, Li C, Wang X, et al. Magnetic monodisperse Fe3O4 nanoparticles. Crystal Growth Design 2005; 5: 391-3.
21. Zhang L, Qiao S, Jin Y, et al. Fabrication and size-selective bioseparation of magnetic silica nanospheres with highly ordered periodic mesostructure. Adv. Funct. Mater 2008; 18: 3203-12.
22. Peng X, Wickham J, Alivisatos A. P. Kinetics of II-VI and III-V colloidal semiconductor nanocrystal growth: "focusing" of size distributions. J. Am. Chem. Soc 1998; 120: 5343-4.
23. O'Brien S, Brus L, Murray CB. Synthesis of manodisperse nanoparticles of barium titanatic: toward a generalized strategy of oxide nanoparticle synthesis. J. Am. Chem. Soc 2001; 123: 12085-6.
24. Sun S, Zeng H. Size-Controlled Synthesis of Magnetite Nanoparticles. J. Am. Chem. Soc 2002; 124: 8204-5.
25. Park J, An K, Hwang Y, et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat. Mater 2004; 3: 891-5.
26. Park J, Lee E, Hwang NM, et al. One-nanometer-scale sizecontrolled synethesis of monodisperse magnetic iron oxide nanoparticles. Angew. Chem. Int. Ed 2005; 44: 2872-7.
27. Li Z, Chen H, Bao H, Gao M. One-Pot Reaction to Synthesize Water-Soluble Magnetite Nanocrystals. Chem. Mater 2004; 16: 1391-3.
28. Li Z, Sun Q, Gao M. Preparation of Water-Soluble Magnetite Nanocrystals from Hydrated Ferric Salts in 2-Pyrrolidone: Mechanism Leading to Fe3O4. Angew. Chem. Int. Ed., 2005; 44: 123-6.
29. Jana NR, Chen Y, Peng X. Size-and shape-controlled magnetic (Cr, Mn, Fe, Co, Ni) oxide nanocrystals via a simple and general approach. Chem. Mater 2004; 16: 3931-5.
30. Ge JP, Hu Y, Biasini M, Beyermann WP, Yin Y. Superparamagnetic magnetite colloidal nanocrystal clusters. Angew. Chem. Int. Ed 2007; 46: 4342-5.
31. Deng H, Li X, Peng Q, Wang X, Chen J, Li Y. Monodisperse magnetic single-crystal ferrite microspheres. Angew. Chem. Int. Ed 2005; 44: 2782-5.
32. Liu J, Sun Z, Deng Y, et al. Colloids highly water-dispersible biocompatible magnetite particles with low cytotoxicity stabilized by citrate groups. Angew. Chem. Int. Ed 2009; 48: 5875-9.
33. Xuan S, Wang F, Wang YX, Yu JC, Leung KC. Facile synthesis of size-controllable monodispersed ferrite nanospheres. J. Mater. Chem 2010; 20: 5086-94.
34. Liu C, Zou B, Rondinone AJ, Zhang ZJ. Reverse Micelle Synthesis and Characterization of Superparamagnetic MnFe2O4 Spinel Ferrite Nanocrystallites. J. Phys. Chem 2000: 104; 1141-5.
35. Jia J, Yu JC, Wang YX, Chan KM. Magnetic Nanochains of FeNi(3) Prepared by a Template-Free Microwave-Hydrothermal Method. ACS Appl. Mater. & Inter 2010; 2: 2579-84.
36. Piao Y, Kim J, Bin Na H, et al. Wrap-bake-peel process for nanostructural transformation from b-FeOOH nanorods to biocompatible iron oxide nanocapsules. Nat Mater 2008; 7: 242-7.
37. Zhang WM, Wu XL, Hu JS, Guo YS, Wan LJ. Carbon Coated Fe3O4 Nanospindles as a Superior Anode Material for Lithium-Ion Batteries. Adv. Funct. Mater 2008; 18: 3941-6.
38. Cheng W, Tang K, Qi Y, Sheng J, Liu Z. One-step synthesis of superparamagnetic monodisperse porous Fe3O4 hollow and coreshell spheres. J. Mater. Chem 2010; 20: 1799-1805.
39. Xuan S, Wang F, Lai JM, et al. Synthesis of biocompatible, mesoporous Fe(3)O(4) nano/microspheres with large surface area for magnetic resonance imaging and therapeutic applications. ACS Appl. Mater. & Inter 2011; 3: 237-44.
40. Leung KC, Wang YX, Wang HH, Chak CP, Cheng CH. Biological and magnetic contrast evaluation of shape-selective Mn-Fe nanowires. IEEE Transactions on Nanobioscience 2009; 8: 192-8.
41. Jia J, Yu JC, Zhu XM, Chan KM, Wang YX. An ultra-fast method to synthesize mesoporous magnetite nanoclusters as highly sensitive magnetic resonance probe. J Colloid Interface Sci 2012; 379: 1-7.
42. Mohapatra S, Pramanik N, Ghosh SK, Pramanik P. Synthesis and characterization of ultrafine poly(vinylalcohol phosphate) coated magnetite nanoparticles. J. Nanosci. Nanotechnol 2006; 6: 823-9.
43. Lu X, Niu M, Qiao R, Gao M. Superdispersible PVP-coated Fe3O4 nanocrystals prepared by a "one-pot" reaction. J. Phys. Chem. B 2008; 112: 14390-4.
44. Moghimi SM, Hunter AC. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res 2001; 18: 1-8.
45. Di Marco M, Port M, Couvreur P, Dubernet C, Ballirano P, Sadun C. Structural characterization of ultrasmall superparamagnetic iron oxide (USPIO) particles in aqueous suspension by energy dispersive X-ray diffraction (EDXD). J Am Chem Soc 2006; 128: 10054-9.
46. Pellegrino T, Manna L, Kudera S, et al. Hydrophobic nanocrystals coated with an amphiphilic polymer shell: A general route to water soluble nanocrystals. Nano Lett 2004; 4: 703-7.
47. Zhang T, Ge J, Hu Y, Yin Y. A general approach for transferring hydrophobic nanocrystals into water. Nano Lett 2007; 7: 3203-7.
48. Bai F, Wang D, Huo Z, et al. A versatile bottom-up assembly approach to colloidal spheres from nanocrystals. Angew. Chem. Int. Ed 2007; 46: 6650-3.
49. Zhuang J, Wu H, Yang Y, Cao Y. Controlling colloidal superparticleg growth through solvophobic interactions. Angew. Chem. Int. Ed 2008; 47: 2208-12.
50. Im SH, Herricks T, Lee YT, Xia YN. Synthesis and characterization of monodisperse silica colloids loaded with superparamagnetic iron oxide nanoparticles. Chem. Phys. Lett 2005; 401: 19-23.
51. Ge J, He L, Goebl J, Yin Y. Assembly of Magnetically Tunable Photonic Crystals in NonpolarSolvents, J. Am. Chem. Soc 2009; 131: 3484-6.
52. Ge J, Hu Y, Zhang T, Yin, Y. Superparamagnetic Composite colloids with anisotropic structures. J. Am. Chem. Soc 2007; 129: 8974-5.
53. Xu Z, Hou Y, Sun S. Magnetic core/Shell Fe3O4/Au and Fe3O4/Au/Ag nanoparticles with tunable plasmonic properties. J Am. Chem. Soc 2007; 129: 8698-9.
54. Xuan S, Wang YX, Leung KCF, Shu K. Synthesis of Fe3O4@polyaniline core/shell microspheres with well-defined blackberry-like morphology. J. Phys. Chem. C 2008; 112: 18804-9.
55. Xuan S, Wang YX, Yu JC, Leung KC. Preparation, characterization and catalytic activity of core/shell Fe3O4@polyaniline@Au nanocomposites. Langmuir 2009; 25: 11835-43.
56. Vestal CR, Zhang ZJ. Atom transfer radical polymerization synthesis and magnetic characterization of MnFe2O4/Polystyrene core/shell nanoparticles. J. Am. Chem. Soc 2002; 124: 14312-3.
57. Lan F, Liu KX, Jiang W, Zeng XB, Wu Y, Gu ZW. Facile synthesis of monodisperse superparamagnetic Fe3O4/PMMA composite nanospheres with high magnetization. Nanotechnology 2011; 22: 225604.
58. Zhang H, Zhong X, Xu JJ, Chen HY. Fe3O4/Polypyrrole/Au nanocomposites with core/shell/shell structure: synthesis, characterization, and their electrochemical properties. Langmuir 2008; 24: 13748-52.
59. You LJ, Xu S, Ma WF, et al. Ultrafast hydrothermal synthesis of high quality magnetic core phenol-formaldehyde shell composite microspheres using the microwave method. Langmuir 2012; 28: 10565-72.
60. Sun X, Li Y. Colloidal carbon spheres and their core/shell structures with Noble-metal nanoparticles. Angew. Chem. Int. Ed 2004; 43: 597-601.
61. Xuan S, Hao L, Jiang W, Gong X, Hu Y, Chen Z. A facile method to fabricate carbon-encapsulated Fe3O4 core/shell composites. Nanotechnology 2007; 18: 035602.
62. Wang H, Sun YB, Chen QW, Yu YF, Cheng K. Synthesis of carbon-encapsulated superparamagnetic colloidal nanoparticles with magnetic-responsive photonic crystal property. Dalton Trans 2010; 39: 9565-9.
63. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv. Mater 2007; 19: 3163-66.
64. Wang B, Xu C, Xie J, Yang Z, Sun S. pH controlled release of chromone from chromone-Fe3O4 nanoparticles. J. Am. Chem. Soc 2008; 130: 14436-7.
65. Xu C, Xu K, Gu H, et al. Nitrilotriacetic acid-modified magnetic nanoparticles as a general agent to bind histidine-tagged proteins. J Am Chem Soc 2004; 126: 3392-3.
66. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003; 24: 1001-11.
67. Villanueva A, Cañete M, Roca AG, et al. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009; 20: 115103.
68. Osaka T, Nakanishi T, Shanmugam S, Takahama S, Zhang H. Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells. Colloids Surf B Biointerfaces. 2009; 71: 325-30.
69. Corot C, Port M, Guilbert I, et al. Superparamagnetic contrast agents. In: Molecular and Cellular MR Imaging. Modo MMJ and Bulte JWM (eds), CRC Press, Boca Raton, FL, USA, 2007, 59-83.
70. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004; 39(1): 56-63.
71. Chao Y, Parmali PP, Simberg D. Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles. In E. Zahavy et al. (eds). Nano-Biotechnology for Biomedical and Medical Research. Advances in Experimental Medicine and Biology 2012, Springer-Verlag, 115-123.
72. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 2000; 11(6): 941-6.
73. Weissleder R, Moore A, Mahmood U, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000; 6: 351-5.
74. Bulte JW, Zhang S, van Gelderen P, et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999; 96: 15256-61.
75. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-4.
76. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999; 10: 186-91.
77. Dodd CH, Hsu HC, Chu WJ, et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivatorpeptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001; 256: 89-105.
78. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 2006; 3: 554-62.
79. Strand BL, Ryan TL, In't Veld P, et al. Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant 2001; 10: 263-75.
80. Metz S, Bonaterra G, Rudelius M, et al. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004; 14: 1851-8.
81. Petri-Fink A, Hofmann H. Superparamagnetic iron oxide nanoparticles (SPIONs): From synthesis to in vivo studies-A summary of the synthesis, characterization, in vitro, and in vivo investigations of SPIONs with particular focus on surface and colloidal properties. IEEE Trans on Nanobioscience 2007; 6: 289-97.
82. Matuszewski L, Persigehl T, Wall A, et al. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology 2005; 235: 155-61.
83. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008; 29: 3583-90.
84. Zhu XM, Wang YX, Leung KC, et al. Enhanced cellular uptake of aminosilane coated superparamagnetic iron oxide nanoparticles in mammalian cell lines. Int J Nanomedicine 2012; 7: 953-64.
85. Wang HH, Wang YX, Leung KC, et al. Durable mesenchymal stem cell labelling using polyhedral superparamagnetic iron oxide nanoparticles. Chem. Eur. J 2009, 15: 12417-25.
86. Wang YX, Quercy-Jouvet T, Wang HH, et al. Efficacy and durability in direct labeling of mesenchymal stem cells using ultrasmall superparamagnetic iron oxide nanoparticles with organosilica, dextran, and PEG coatings. Materials 2011; 4: 703-15.
87. Wang YX, Leung KC, Cheung WH, et al. Low-intensity pulsed ultrasound increases cellular uptake of superparamagnetic iron oxide nanomaterial: results from human osteosarcoma cell line U2OS. J Magn Reson Imaging 2010; 31: 1508-13.
88. Tanaka T, Sakai R, Kobayashi R, Hatakeyama K, Matsunaga T. Contributions of phosphate to DNA adsorption/desorption behaviors on aminosilane-modified magnetic nanoparticles. Langmuir 2009; 25: 2956-61.
89. Zhang C, Wangler B, Morgenstern B, et al. Silica-and alkoxysilanecoated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging. Langmuir 2007; 23: 1427-34.
90. Kunzmann A, Andersson B, Vogt C, et al. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol 2011; 253: 81-93.
91. Hwang YH, Lee DY. Magnetic resonance imaging using heparincoated superparamagnetic iron oxide nanoparticles for cell tracking in vivo. Quant Imaging Med Surg 2012; 2: 118-23.
92. Lee DY. Highly effective T2 MR contrast agent based on heparinized superparamagnetic iron oxide nanoparticles. Macromolecular Research 2011; 19: 843-847.
93. Lee JH, Jung MJ, Hwang YH, et al. Heparin-coated superparamagnetic iron oxide for in vivo MR imaging of human MSCs. Biomaterials 2012; 33: 4861-4871.
94. Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004; 104: 1217-23.
95. Jung MJ, Lee SS, Hwang YH, et al. MRI of transplanted surfacelabeled pancreatic islets with heparinized superparamagnetic iron oxide nanoparticles. Biomaterials 2011; 32: 9391-400.
96. Moon HJ, Yun YP, Han CW, et al. Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function. Biochem Biophys Res Commun 2011; 413: 194-200.
97. Shen H, Hu X, Yang F, Bei J, Wang S. Cell affinity for bFGF immobilized heparin-containing poly(lactide-co-glycolide) scaffolds. Biomaterials 2011; 32: 3404-12.
98. Gozal E, Ortiz LA, Zou X, Burow ME, Lasky JA, Friedman M. Silica-induced apoptosis in murine macrophage: involvement of tumor necrosis factor-alpha and nuclear factor-kappaB activation. Am J Respir Cell Mol Biol 2002; 27: 91-8.
99. Shapiro EM, Medford-Davis LN, Fahmy TM, Dunbar CE, Koretsky AP. Antibody-mediated cell labeling of peripheral T cells with micron-sized iron oxide particles (MPIOs) allows single cell detection by MRI. Contrast Media Mol Imaging 2007; 2: 147-53.
100. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 1989; 152: 167-73.
101. Lee JM, Kim IH, Kwak HS, Youk JH, Han YM, Kim CS. Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT. Korean J Radiol 2003; 4: 1-8.
102. Ba-Ssalamah A, Uffmann M, Saini S, Bastati N, Herold C, Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009; 19: 342-57.
103. Tanaka M, Nakashima O, Wada Y, Kage M, Kojiro M. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 1996; 24: 807-12.
104. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast materialenhanced MR imaging. Radiology 2006; 239: 425-37.
105. Wang YX. Comments on Jing et al. original article "In vivo MR imaging tracking of magnetic iron oxide nanoparticle labeled, engineered, autologous bone marrow mesenchymal stem cells following intra-articular injection. " Joint Bone Spine 2009; 76: 118-9.
106. Wang YX, Wang HH, Au DWT, Zuo BS, Teng LS. Pitfalls in employing superparamagnetic iron oxide particles for stem cell labeling and in vivo MRI tracking. Br J Radiol 2008; 81: 987-8.
107. Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1. 5 T clinical MRI scanner. Magn Reson Med 2003; 49: 968-71.
108. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med 2006; 55: 242-9.
109. Schäfer R, Bantleon R, Kehlbach R, et al. Functional investigations on human mesenchymal stem cells exposed to magnetic fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol 2010; 11: 22.
110. Schäfer R, Kehlbach R, Müller M, et al. Labeling of human mesenchymal stromal cells with superparamagnetic iron oxide leads to a decrease in migration capacity and colony formation ability. Cytotherapy 2009; 11: 68-78.
111. Syková E, Jendelová P. Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord. Ann N Y Acad Sci 2005; 1049: 146-60.
112. Sigovan M, Kaye E, Lancelot E, et al. Anti-Inflammatory Drug Evaluation in ApoE/-Mice by Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging. Invest Radiol 2012; 47: 546-552.
113. Wang YX, Lam WW. Characterisation of brain disorders and evaluation of therapy by functional and molecular magnetic resonance techniques. Hong Kong Med J 2008; 14: 469-78.
114. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Mödder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004; 127: 1670-7.
115. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Am J Neuroradiol 2006; 27: 1000-5.
116. Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol 2004; 30: 456-71.
117. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected in vivo magnetic resonance imaging, Circulation 2003, 107: 2453-8.
118. Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol 2006; 26: 1601-6.
119. Tang T, Howarth SP, Miller SR, et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using highresolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 2006; 37: 2266-70.
120. Trivedi RA, U-King-Im JM, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004; 35: 1631-5.
121. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magneticresonance imaging in carotid disease. J Am Coll Cardiol 2009; 53: 2039-50.
122. Yancy AD, Olzinski AR, Hu TC, et al. Differential uptake of ferumoxtran-10 and ferumoxytol ultrasmall superparamagnetic iron oxide contrast agents in rabbits: critical determinants of atherosclerotic plaque labelling, J. Magn. Reson. Imaging 2005; 21: 432-42.
123. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?. " J Am Coll Cardiol 2009; 53: 2051-2052.
124. Patterson AJ, Tang TY, Graves MJ, Müller KH, Gillard JH. In vivo carotid plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. NMR Biomed 2011; 24: 89-95.
125. Kinner S, Maderwald S, Parohl N, et al. Contrast-enhanced magnetic resonance angiography in rabbits: evaluation of the gadolinium-based agent p846 and the iron-based blood pool agent p904 in comparison with gadoterate meglumine. Invest Radiol 2011; 46: 524-529.
126. Moeller S, Freiwald WA, Tsao DY. Patches with link: a unified system fro processing faces in the macaque temporal lobe. Science 2008; 320: 1355-1359.
127. Smirnakis SM, Schmid MC, Weber B, Tolias AS, Augath M, Logothetis NK. Spatial specificity of BOLD versus cerebral blood volume fMRI for mapping cortical organization. J Cereb Blood Flow Metab 2007; 27: 1248-1261.
128. Leite FP, Tsao D, Vanduffel W, Fize D, Sasaki Y, Wald LL, Dale AM, Kwong KK, Orban GA, Rosen BR, Tootell RB, Mandeville JB. Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla. Neuroimage 2002; 16: 283-94.
129. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 2006; 5: 411-424.
130. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
131. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14: 1310-6.
132. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2007; 2: 415-23.
133. Mahmoudi M, Simchi A, Imani M, Hafeli UO. Superparamagnetic iron oxide nanoparticles with rigid cross-linked polyethylene glycol fumarate coating for application in imaging and drug delivery. J Phys Chem C 2009; 113: 8124-31.
134. Guo S, Li D, Zhang L, Li J, Wang E. Monodisperse mesoporous superparamagnetic single-crystal magnetite nanoparticles for drug delivery. Biomaterials 2009; 30: 1881-9.
135. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 2000; 17: 309-15.
136. Gonzales M, Krishnan KM. Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mater 2005; 293: 265-70.
137. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv Mater 2006; 18: 1345-60.
138. Babincová M, Cicmanec P, Altanerová V, Altaner C, Babinec P. Magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 2002; 55: 17-9.
139. Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res 2011; 2: 81-7.
140. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials 2009; 30: 6748-56.
141. Chen Y, Chen H, Zeng D, et al. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano 2010; 4: 6001-13.
142. Cheng W, Tang K, Qi Y, Sheng J, Liu Z. One-step synthesis of superparamagnetic monodisperse porous Fe3O4 hollow and coreshell spheres. J. Mater. Chem 2010; 20: 1799-1805.
143. Iram M, Guo C, Guan Y, Ishfaq A, Liu H. Adsorption and magnetic removal of neutral red dye from aqueous solution using Fe3O4 hollow nanospheres. J. Hazard. Mater 2010; 181: 1039-50.
144. Zhu XM, Yuan J, Leung KC, et al. Hollow superparamagnetic iron oxide nanoshells as a hydrophobic anticancer drug carrier: intracelluar pH-dependent drug release and enhanced cytotoxicity. Nanoscale 2012; 4: 5744-54.
145. Wilson MW, Kerlan RK Jr, Fidelman NA, et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology 2004; 230: 287-93.
146. Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv Pharmacol Chemother 1979; 16: 213-71.
147. Alexiou C, Jurgons R, Schmid RJ, et al. Magnetic drug targeting: Biodistribution of the magnetic carrier and the chemotherapeutic agnet mitoxantrone after locoregional cancer treatment. J. Drug Targeting 2003; 11: 139-49.
148. Grief AD, Richardson G. Mathematical modelling of magnetically targeted drug delivery. J Magn Magn Mater 2005; 293: 455-63.
149. Rosengart AJ, Kaminski MD, Chen H, Caviness PL, Ebner AD, Ritter JA. Magnetizable implants and functionlized magnetic cariers: A novel approch for nonivasive yet targeted drug delivery. J. Magn. Magn. Mater 2005; 293: 633-8.
150. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 2000; 17: 309-15.
151. Forbes ZG, Yellen BB, Halverson DS, Fridman G, Barbee KA, Friedman G. Validation of high gradient magnetic field based drug delivery to magnetizable implants under flow. IEEE Trans Biomed Eng 2008; 55: 643-9.
152. Yellen BB, Forbes ZG, Halverson DS, et al. Targeted drug delivery tomagnetic implants for therapeutic applications. J Magn Magn Mater 2005; 293: 647-54.
153. Lübbe AS, Bergemann C, Huhnt W, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996; 56: 4694-701.
154. Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996; 56: 4686-93.
155. Inada Y, Ohwada K, Yoshimoto T, et al. Fibrinolysis by urokinase endowed with magnetic property. Biochem Biophys Res Commun 1987; 148: 392-6.
156. Viroonchatapan E, Ueno M, Sato H, et al. Preparation and characterization of dextran magnetite-incorporated thermosensitive liposomes: An on-line flow system for quantifying magnetic responsiveness. Pharm Res 1995; 12: 1176-83.
157. Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment. Eur J Pharm Sci 2011; 44: 1-10.
158. Wang YX. Transcatheter embolisation therapy in liver cancer. Recent Patents on Medical Imaging 2012; 2: 150-162.
159. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focalmalignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000; 174: 323-31.
160. Jang B, Park S, Kang SH, et al. Gold nanorods for target selective SPECT/CT imaging and photothermal therapy in vivo. Quant Imaging Med Surg 2012; 2: 1-11.
161. Atsumi T, Jeyadevan B, Sato Y, Tohji K, Fundamental studies of hyperthermia using magnetic particles as thermoseeds 1: Development of magnetic particles suitable for hyperthermia. J. Magn. Soc. Jpn 2006, 30: 555-60.
162. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J. Biosci. Bioeng 2003; 96: 364-9.
163. Shinkai M, Suzuki M, Iijima S, Kobayashi T. Antibodyconjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia. Biotechnol. Appl. Biochem 1994; 21: 125-37.
164. Shinkai M, Le B, Honda H, et al. Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn. J. Cancer Res 2001 92: 1138-45.
165. Ito A, Kuga Y, Honda H, et al. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 2004; 212: 167-75.
166. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci 2011; 166: 8-23.
167. Yanase M, Shinkai M, Honda H, et al. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn. J. Cancer Res 1998, 89: 775-82.
168. Ballauff M, Lu Y. 'Smart nanoparticles': preparation, characterization and applications. Polymer 2007; 48: 1815-23.
169. Johannsen M, Gneveckow U, Eckelt L, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. Int. J. Hyperthermia 2005; 21: 637-47.
170. Moroz P, Jones SK, Winter J, Gray BN. Targeting liver tumours with hyperthermia: ferromagnetic embolization in a rabbit liver tumour model. J. Surg. Oncol 2001; 78: 22-9.
171. Moroz P, Metcalf C, Gray BN. Histologic analysis of liver tissue following hepatic arterial infusion of ferromagnetic particles in a rabbit liver tumour model. Biometals 2003; 16: 455-64.
172. Moroz P, Jones SK, Metcalf C, Gray BN. Hepatic clearance of arterially infused ferromagnetic particles. Int. J. Hyperthermia 2003; 19: 23-34.
173. Dobson J. Magnetic nanoparticle-based gene delivery. Gene Therapy 2006; 13: 283-7.
174. Mah C, Fraites TJ Jr, Zolotukhin I, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol. Therapy 2002; 6: 106-12.
175. Plank C, Schillinger U, Scherer F, et al. The magnetofection method: Using magnetic force to enhance gene delivery. Biol. Chem 2003; 84: 737-47.
176. Kalish H, Arbab AS, Miller BR, et al. Combination of transfection agents and magnetic resonance contrast agents for cellular imaging: Relationship between relaxivities, electrostatic forces, and chemical composition. Magn Reson Med 2003; 50: 275-82.
177. Wang P, Yigit MV, Medarova Z, et al. Combined small interfering RNA therapy and in vivo magnetic resonance imaging in islet transplantation. Diabetes 2011; 60: 565-71.
178. Wang P, Yigit MV, Ran C, et al. A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection. Diabetes 2012; 61: 3247-54.
179. Lu G, Liu PC, Poon WS, et al. Magnetic targeted transcatheter SPIO labeled stem cell delivery: preliminary results in a rat intracerebral hemorrhage model. Proceedings of the European Society for Magnetic Resonance in Medicine and Biology, Antalya 2009: No. 299.
180. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, Marbán E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010; 106: 1570-81.
181. Wang YX, Wang DW, Zhu XM, Zhao F, Leung KC. Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quant Imaging Med Surg 2012; 2: 53-6.
182. Cartmell SH, Dobson J, Verschueren SB, El Haj AJ. Development of magnetic particle techniques for long term culture of bone cells with intermittent mechanical activation. IEEE Trans. NanoBiosci 2002; 1: 92-7.
183. Dobson J, Cartmell SH, Keramane A, El Haj AJ. Principles and design of a novel magnetic force mechanical conditioning Bioreactor for tissue engineering, stem cell conditioning, and dynamic in vitro screening. IEEE Trans. NanoBiosci 2006; 5: 173-7.
184. Hughes S, McBain S, Dobson J, El Haj AJ. Selective activation of mechanosensitive ion channels using magnetic particles. J. Roy. Soc. Interface 2008; 5: 855-63.
185. Lin MM, Kim do K, El Haj AJ, Dobson J. Development of superparamagnetic iron oxide nanoparticles (SPIONS) for translation to clinical applications. IEEE Trans Nanobioscience 2008; 7: 298-305.
186. Ito A, Takizawa Y, Honda H, et al. Tissue engineering using magnetite nanoparticles and magnetic force: Heterotypic layers of cocultured hepatocytes and endothelial cells. Tissue Eng 2004; 10: 833-40.
187. Ito A, Ino K, Hayashida M, et al. Novel methodology for fabrication of tissue-engineered tubular constructs using magnetite nanoparticles and magnetic force. Tissue Eng 2005; 11: 1553-61.
188. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjugate Chem 2011; 22: 1879-1903.
189. Khurana A, Nejadnik H, Gawande R, et al. Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants. Radiology 2012; 264: 803-11.
190. Bulte JW. Science to practice: can macrophage infiltration serve as a surrogate marker for stem cell viability? Radiology 2012; 264: 619-20.
191. Halamoda Kenzaoui B, Chapuis Bernasconi C, Guney-Ayra S, Juillerat-Jeanneret L. Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J 2012; 441: 813-21.
192. Miller I, Ashton-Chess J, Spolders H, et al. Market access challenges in the EU for high medical value diagnostic tests. Personalized Med 2011; 8: 137-48.
193. Wang YX, Deng M. Medical imaging in new drug clinical development. J Thorac Dis 2010; 2: 245-52.
194. Wang YX. Medical imaging in pharmaceutical clinical trials: what radiologists should know. Clin Radiol 2005; 60: 1051-7.
195. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug 2012; 11: 201-14.